Discovered by BIOTEC research team together with the Medicines for Malaria Venture (MMV), the patented P218 compound was designed based-on 3-dimensional structures of malaria protein target, dihydrofolate reductase, in order to circumvent mutations that had led to resistance to pyrimethamine, […]
Recent Posts
